Codiak BioSciences, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 27 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-08-16: Reporting owner Pandite Arundathy N.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-08-09: Reporting owner Sathyanarayanan Sriram; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-08-06: Reporting owner Sathyanarayanan Sriram; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-06-22: Reporting owner Sathyanarayanan Sriram; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-08-16 | Pandite Arundathy N. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $19.65 exercise price | 2021-08-18 | |
| 2021-08-09 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +1,300 48,666 owned after | $3.29 exercise price | 2021-09-28 | |
| 2021-08-06 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +1,300 49,966 owned after | $3.29 exercise price | 2021-09-28 | |
| 2021-06-22 holding as of filing | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.29 exercise price | 2021-06-22 | ||
| 2021-06-22 holding as of filing | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.17 exercise price | 2021-06-22 | ||
| 2021-06-22 holding as of filing | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.25 exercise price | 2021-06-22 | ||
| 2021-06-22 holding as of filing | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.25 exercise price | 2021-06-22 | ||
| 2021-06-22 holding as of filing | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.25 exercise price | 2021-06-22 | ||
| 2021-06-22 holding as of filing | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $26.60 exercise price | 2021-06-22 | ||
| 2021-06-18 | Bernstein Karen Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $24.13 exercise price | 2021-06-22 | |
| 2021-06-18 | COONEY CHARLES L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $24.13 exercise price | 2021-06-22 | |
| 2021-06-18 | GILLIS STEVEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $24.13 exercise price | 2021-06-22 | |
| 2021-06-18 | Haddock Jason Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $24.13 exercise price | 2021-06-22 | |
| 2021-06-18 | MELAS KYRIAZI THEO Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $24.13 exercise price | 2021-06-22 | |
| 2021-06-09 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $26.76 exercise price | 2021-06-22 | |
| 2021-06-08 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +7,276 92,978 owned after | $3.29 exercise price | 2021-09-28 | |
| 2021-06-08 | Sorensen Benny Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +8,533 87,411 owned after | $3.29 exercise price | 2021-09-28 | |
| 2021-05-17 | Eggimann Anne-Virginie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $18.48 exercise price | 2021-05-21 | |
| 2021-05-10 | Wheler Jennifer J. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $16.41 exercise price | 2021-05-12 | |
| 2021-01-22 | Verma Ajay Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,000 29,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | Bain Linda Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,000 58,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | Howze Yalonda Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | Konstantinov Konstantin Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,000 32,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | Brudnick Richard Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,000 31,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | Barna Nicole Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,000 24,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | WILLIAMS DOUGLAS E Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −175,000 175,000 owned after | $26.60 exercise price | 2021-01-26 | |
| 2021-01-22 | Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,000 31,000 owned after | $26.60 exercise price | 2021-01-26 |